Matritech, Bayer to collaborate on NMP-based cervical cancer screening test.
This article was originally published in The Gray Sheet
Executive Summary
BAYER WILL FUND MATRITECH'S SEARCH FOR CERVICAL CANCER NMP as part of a product development and marketing option agreement between the two companies, Matritech says. Under the agreement announced June 14, Bayer (formerly Miles Diagnostics) will work on developing an automated cervical cancer screening test based on Matritech's nuclear matrix protein (NMP) technology. The test is intended to replace the standard Pap smear method of cervical cancer screening.